The Renoprotective Effect of Linagliptin in Type 2 Diabetic Patients with Severely Increased Albuminuria.

Introduction: Previous studies have suggested that linagliptin may represent renoprotective effects besides its anti-hyperglycemic properties in patients with type 2 diabetes. However, there is a lack of decisive evidence to support this assumption. This study aimed to address the effect of linagliptin in type 2 diabetic patients with severely increased albuminuria.

Does Omega-3 supplementation decrease carotid intima-media thickening in hemodialysis patients?

Objective: A randomized, double-blind, placebo-controlled clinical trial was performed to assess the effect of omega-3 supplementation (3 g/day) on atherosclerosis progression by measuring carotid intima-media thickness (cIMT) in hemodialysis (HD) patients.

Methods: A total of 54 HD patients were randomized into two groups: Intervention group ( = 27), in which patients were given 3 g/day omega-3 for 6 months and placebo group ( = 27), in which patients received placebo using the same administration protocol. All patients underwent a carotid artery ultrasound scan to measure cIMT at baseline and at 6 months.

Low-dose pamidronate for treatment of early bone loss following kidney transplantation: a randomized controlled trial.

Introduction: Kidney transplantation is associated with rapid loss of bone mineral density (BMD) in the first months after transplantation. The effect of pamidronate on bone loss after transplantation was evaluated in a randomized controlled trial.

Materials And Methods: Forty patients were enrolled in this study (16 in the pamidronate group and 24 in the control group).